Cargando…

Forecasting Clinical Dose–Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin

A crucial step for accelerating tuberculosis drug development is bridging the gap between preclinical and clinical trials. In this study, we developed a preclinical model‐informed translational approach to predict drug effects across preclinical systems and early clinical trials using the in vitro‐b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wicha, Sebastian G., Clewe, Oskar, Svensson, Robin J., Gillespie, Stephen H., Hu, Yanmin, Coates, Anthony R.M., Simonsson, Ulrika S.H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282494/ https://www.ncbi.nlm.nih.gov/pubmed/29700814 http://dx.doi.org/10.1002/cpt.1102

Ejemplares similares

A model-based analysis identifies differences in phenotypic resistance between in vitro and in vivo: implications for translational medicine within tuberculosis
por: Clewe, Oskar, et al.
Publicado: (2020)

A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro
por: Clewe, Oskar, et al.
Publicado: (2016)

Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictions
por: Faraj, Alan, et al.
Publicado: (2020)

A pharmacometric pulmonary model predicting the extent and rate of distribution from plasma to epithelial lining fluid and alveolar cells—using rifampicin as an example
por: Clewe, Oskar, et al.
Publicado: (2015)

A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions
por: Wicha, Sebastian G., et al.
Publicado: (2017)

A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses
por: Svensson, Robin J., et al.
Publicado: (2017)

A model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations
por: Clewe, Oskar, et al.
Publicado: (2018)

Rifampicin Can Be Given as Flat-Dosing Instead of Weight-Band Dosing
por: Susanto, Budi O, et al.
Publicado: (2019)

Evaluation of optimized bronchoalveolar lavage sampling designs for characterization of pulmonary drug distribution
por: Clewe, Oskar, et al.
Publicado: (2015)

Application of the Multistate Tuberculosis Pharmacometric Model in Patients With Rifampicin‐Treated Pulmonary Tuberculosis
por: Svensson, RJ, et al.
Publicado: (2016)

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis
por: Svensson, Elin M, et al.
Publicado: (2018)

Mobile Health Apps for Improvement of Tuberculosis Treatment: Descriptive Review
por: Keutzer, Lina, et al.
Publicado: (2020)

Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing—Using Rifampicin as an Example
por: Keutzer, Lina, et al.
Publicado: (2020)

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin
por: Keutzer, Lina, et al.
Publicado: (2022)

Improved power for TB Phase IIa trials using a model-based pharmacokinetic–pharmacodynamic approach compared with commonly used analysis methods
por: Svensson, Robin J., et al.
Publicado: (2017)

Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development
por: Ayoun Alsoud, Rami, et al.
Publicado: (2023)

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis
por: Stemkens, Ralf, et al.
Publicado: (2023)

Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis
por: te Brake, Lindsey H. M., et al.
Publicado: (2019)

Rifampicin Resistance in Tuberculosis Outbreak, London, England
por: Jenkins, Claire, et al.
Publicado: (2005)

A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation
por: Khadka, Prakash, et al.
Publicado: (2022)

High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo
por: Hu, Yanmin, et al.
Publicado: (2015)

Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP)
por: Ekqvist, David, et al.
Publicado: (2022)

Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of in vitro, in vivo methodologies and human studies
por: Alffenaar, Jan-Willem C., et al.
Publicado: (2022)

Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India
por: Aruldhas, Blessed Winston, et al.
Publicado: (2019)

Concentrations of rifampicin in pre-dose samples in patients with pulmonary tuberculosis
por: Uchoa, Breno Kristoffer Beleza, et al.
Publicado: (2019)

High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre
por: Seijger, Charlotte, et al.
Publicado: (2019)

Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg(−1) rifampicin
por: te Brake, Lindsey H.M., et al.
Publicado: (2021)

Could high-concentration rifampicin kill rifampicin-resistant M. tuberculosis? Rifampicin MIC test in rifampicin-resistant isolates from patients with osteoarticular tuberculosis
por: Zhang, Zehua, et al.
Publicado: (2014)

Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients
por: Faraj, Alan, et al.
Publicado: (2020)

Improving treatment outcome assessment in a mouse tuberculosis model
por: Mourik, Bas C., et al.
Publicado: (2018)

Airway microecology in rifampicin-resistant and rifampicin-sensitive pulmonary tuberculosis patients
por: Cai, Xingshan, et al.
Publicado: (2022)

Assessing Pharmacodynamic Interactions in Mice Using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models
por: Chen, Chunli, et al.
Publicado: (2017)

Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis
por: Mockeliunas, Laurynas, et al.
Publicado: (2022)

Medical Device Apps: An Introduction to Regulatory Affairs for Developers
por: Keutzer, Lina, et al.
Publicado: (2020)

The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis
por: Abulfathi, Ahmed A., et al.
Publicado: (2021)

A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients
por: Kaboggoza, Julian P, et al.
Publicado: (2019)

High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
por: Decroo, Tom, et al.
Publicado: (2020)

The multistate tuberculosis pharmacometric model: a semi-mechanistic pharmacokinetic-pharmacodynamic model for studying drug effects in an acute tuberculosis mouse model
por: Chen, Chunli, et al.
Publicado: (2017)

Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence
por: Rockwood, Neesha, et al.
Publicado: (2017)

Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data
por: Mudde, Saskia E, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_46uqkpq471ed4ispup6p3s1899